RHHBY Stock Recent News

Roche's Q1 revenues beat Street consensus, but key growth products underperformed, making the beat less appealing. Mid-sized products like Phesgo, Xolair, and Polivy drove the revenue beat, compensating for the underperformance of larger products. The diagnostics division faced pricing headwinds in China, impacting overall performance, but other geographies helped offset the decline and resulted in flat revenues for the division.

Swiss pharma giant Roche said it will invest US$50 billion into the US in the next five years to ensure it exports more medicines from the country than it imports, amid threats of potential tariffs on the sector from President Donald Trump. The Basel-headquartered group said it will expand and upgrade US manufacturing and distribution capabilities for its medicines and diagnostics tests in Kentucky, Indiana, New Jersey, Oregon and California, where it Other planned investments were flagged, including new manufacturing facilities for gene therapy in Pennsylvania and continuous glucose monitoring in Indiana, with a new manufacturing centre for its weightloss medicines in a location to be announced.

Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collection Quest also plans to make self-collection option available at its 2,000 patient service centers in the United States early next month, expanding access to screening New solution follows company's launch of GTI self-collection option for several STIs and related conditions last fall SECAUCUS, N.J. , April 2, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a new solution aimed at broadening access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer.

Dublin, March 03, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: F. Hoffmann - La Roche Ltd 2024" report has been added to ResearchAndMarkets.com's offering.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored Phase III OUtMATCH study, which provide further evidence supporting the role of Xolair® (omalizumab) for the treatment of one or more food allergies. Stage 2 of the OUtMATCH study showed Xolair was more effective with fewer side effects than multi-allergen oral immunother.

Roche Holding AG (OTCQX:RHHBY) Q4 2024 Earnings Conference Call January 30, 2025 8:00 AM ET Company Participants Thomas Schinecker - CEO Alan Hippe - Chief Financial & Information Officer Teresa Graham - CEO, Roche Pharmaceuticals Matt Sause - CEO, Roche Diagnostics Bruno Eschli - Head, IR Conference Call Participants Richard Vosser - JPMorgan Emily Field - Barclays Sachin Jain - Bank of America Matthew Weston - UBS Simon Baker - Redburn James Quigley - Goldman Sachs Richard Parkes - BNP Rajesh Kumar - HSBC Justin Smith - Bernstein Benjamin Jackson - Jefferies Operator [Starts Abruptly] If you note that the webinar is being recorded. I'd like to inform you that all participants are in listen-only mode, during the call.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the overall survival (OS) analysis of the Phase III INAVO120 study investigating ItovebiTM (inavolisib) in combination with palbociclib (Ibrance®) and fulvestrant for people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, endocrine-resistant, locally advanced or metastatic b.

Basel, 11 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (FDA) approved Itovebi™ (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. The PIK3CA mutation is found in approximately 40% of HR-positive metastatic breast cancers.2

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Roche Holding AG (RHHBY) and AbbVie (ABBV). But which of these two stocks is more attractive to value investors?

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.